Vimian Group AB (publ) (VIMIAN.ST) Research

Vimian Group AB (publ) operates as a global enterprise in the animal health sector, segmenting its business into Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. Through its Nextmune brand, the company delivers a comprehensive portfolio of proprietary diagnostic tools and both prescription and non-prescription therapies designed for the preventive care and ongoing management of chronic conditions in companion animals. The Indical Bioscience division provides specialized molecular and immunodiagnostic solutions, predominantly employed by laboratories for veterinary-specific applications across both livestock and companion animal health markets. Additionally, the VetFamily brand runs a membership-based platform that furnishes veterinary clinics with crucial procurement services, technology-enabled operational support (including online marketing, education, and human resources), and fosters a professional community. Finally, Movora is responsible for supplying orthopedic implants to veterinarians and academic institutions. Founded in 2020, Vimian Group's headquarters are located in Stockholm, Sweden.

Market snapshot

Symbol
VIMIAN.ST
Price
$29.60
Day change
-3.27%
Market cap
$1.4B
P/E ratio
38.77x
52-week range
24.18-43.58
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Next earnings
in 25 days

Peer companies

  • AddLife AB (publ) (ALIF-B.ST)
  • Ambea AB (publ) (AMBEA.ST)
  • Arjo AB (publ) (ARJO-B.ST)
  • Attendo AB (publ) (ATT.ST)
  • BioGaia AB (publ) (BIOG-B.ST)
  • Bonesupport Holding AB (publ) (BONEX.ST)
  • Elekta AB (publ) (EKTA-B.ST)
  • RaySearch Laboratories AB (publ) (RAY-B.ST)

Open Vimian Group AB (publ) (VIMIAN.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.